20-F: Altamira Therapeutics Repositions for RNA Delivery Focus, Reports Annual Results

Altamira Therapeutics shifts focus to RNA delivery technology, divesting legacy assets and reporting its financial results for the year ended December 31, 2024.

Summary

• Altamira Therapeutics is strategically repositioning to focus on RNA delivery technology, particularly its xPhore platform.
• The company divested a 51% stake in Altamira Medica AG (Bentrio business) in 2023 and intends to divest or partner its remaining legacy assets in 2025.
• Key programs include AM-401 (KRAS driven cancer) and AM-411 (rheumatoid arthritis), both in preclinical development.
• The company reported a net loss of $8.46 million from continuing operations for 2024.
• Research and development expenses were $3.73 million in 2024, up from $3.38 million in 2023.
• The company had cash and cash equivalents of $0.99 million as of December 31, 2024.
• Altamira is seeking additional funding to continue its research and development programs, raising concerns about its ability to continue as a going concern.
• Management concluded that the Companys internal control over financial reporting was effective as of December 31, 2024, after remediating material weaknesses identified in prior years.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the strategic shift towards RNA delivery and remediation of internal control weaknesses are positive, the significant net losses, dependence on additional funding, and going concern uncertainty weigh negatively on the overall outlook.

Positives

• Strategic shift towards RNA delivery technology with high potential.
• Advancement of AM-401 and AM-411 programs into preclinical development.
• Remediation of previously identified material weaknesses in internal control over financial reporting.
• Collaboration agreements with biopharmaceutical companies to leverage the xPhore platform.

Negatives

• Significant net losses from continuing operations.
• Dependence on additional funding to continue research and development programs.
• Going concern uncertainty due to limited cash reserves.
• Delisting from Nasdaq and subsequent trading on OTCQB.

Risks

• The company's product candidates are still in the development stage and it has a limited operating history and a history of operating losses.
• The company expects that it will need substantial additional funding before it can expect to become profitable from out-licensing its RNA delivery platforms and product candidates, and there is substantial doubt about its ability to continue as a going concern.
• Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our intellectual property or future revenue streams.
• Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.
• If the company fails to maintain its current strategic relationship with Washington University, its business, commercialization prospects and financial condition may be materially adversely affected.

Future Outlook

The company aims to expand collaborations with biopharmaceutical companies to leverage its xPhore platform and generate revenues from contract development and manufacturing, milestone payments, and royalties. Altamira is aiming to achieve IND clearance with either AM-401 or AM-411 in 2026.

Industry Context

The document highlights the competitive landscape in the biopharmaceutical industry, particularly in RNA delivery technologies, KRAS driven cancers, and rheumatoid arthritis. It mentions key competitors and existing treatments, providing context for Altamira's strategic positioning and product development efforts.

Comparison to Industry Standards

• The report mentions competitors in the RNA delivery space such as Acuitas Therapeutics Inc., Aposense Ltd., and Genevant Sciences Corp.
• In the KRAS driven cancer space, Amgen and Mirati Therapeutics are mentioned as having FDA approved treatments.
• For rheumatoid arthritis, AbbVie, Johnson & Johnson, Roche, BMS, and Lilly are identified as key players with marketed biologics and small molecule JAK inhibitors.

Related Party Transactions

• The Company held a receivable of $331,511 against Altamira Medica AG (Medica) as of December 31, 2024.
• The Company re-charged personnel costs in the amount of $661,308 for its services to the associated company Medica.
• PharmaTrail AG, a company founded by our Chief Executive Officer Thomas Meyer and led by Dominik Lysek as Chief Executive Officer, has been renting part of our office space in Basel, Switzerland, under a sublease agreement.
• Gremaud GmbH provides the Chief Financial Officer to the Company since November 19, 2021.
• Samuel Wickline, Ph.D., the founder of Trasir, has been providing consulting services as Chief Scientific Adviser to the Company since January 2023.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Employees may be affected by potential delays, reductions, or elimination of research and development programs.
• Customers of Bentrio may experience changes in product availability or distribution due to the partial divestiture of Altamira Medica AG.
• Suppliers and creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• Continue development of RNA delivery platforms and product candidates AM-401 and AM-411.
• Seek partnerships or divestiture of remaining legacy assets in 2025.
• Pursue IND clearance for AM-401 or AM-411 by the FDA in 2026.
• Expand collaborations with biopharmaceutical companies for leveraging the xPhore platform.

Key Dates

Keywords

RNA delivery, xPhore platform, AM-401, AM-411, Altamira Therapeutics, financial results, preclinical development, biopharmaceutical, going concern, Bentrio, divestiture